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In 20% of cases, hereditary non-syndromic hearing loss has an autosomal dominant inheritance
(ADNSHL). To date, more than 50 loci for ADNSHL have been mapped to different chromosomal regions.
In order to verify whether genomic alterations contribute to the hearing loss etiology and to search for
novel deafness candidate loci, we investigated probands from families with ADNSHL by oligonucleotide
array-CGH. A deletion in the 5q32 region encompassing only one gene, POU4F3, which corresponds to
DFNA15, was detected in one family. POU4F3 protein has an important role in the maturation, differ-
entiation and survival of cochlear hair cells. Defects in these cells may therefore explain sensorineural
hearing loss. Mutations in this gene have already been associated with autosomal dominant hearing loss
but this is the ﬁrst description of a germline POUF4F3 deletion associated with hearing impairment.
 2014 Elsevier Masson SAS. All rights reserved.
1. Clinical description
Hereditary hearing loss is a clinically and genetically heteroge-
neous sensory disorder that can present several inheritance pat-
terns, including autosomal-dominant inheritance (ADNSHL), which
is observed in about 20% of the cases. In this report case there are
only two ADNSHL affected members in the family, the proband and
his father (Fig. 1). Concomitant disease, surgery, immunization and
any other possible causes of acquired deafness were ruled out. After
ear nose and throat (ENT) examination, pure-tone audiometry
(PTA) was performed along with additional tests, including speech
reception threshold (SRT), word recognition score (WRS) and
tympanometry. Although none of the affected people reported
vestibular symptoms, vestibular function was tested by Electrooc-
ulography (EOG) and Sinusoidal Harmonic Acceleration Test
(SHAT), aiming to reveal any signal of vestibular hair cell damage.
The EOG test incorporated the evaluation of ocular motor tests
including gaze, smooth pursuit, random horizontal saccade and
optokinetic nystagmus responses; and it also evaluated the
vestibulo-ocular reﬂex by caloric stimulus. The SHAT allows
evaluation of bilateral vestibular response at high frequencies of
angular acceleration (0.02, 0.04, 0.16 Hz), complementing the EOG
in which only low frequencies are tested. Otoacoustic emissions
(OAE) and Brain Evoked Response Audiometry (BERA) tests were
also performed. Computed tomography (CT) scanning of the tem-
poral bone and Magnetic Resonance Imaging (MRI) with a contrast
(gadolinium) were obtained.
The proband reported that his hearing loss began at the age of 11
years old, although there is no audiogram conﬁrming a normal
hearing before that age. One year later he had an episode of
appendicitis that was treated by surgical removal of the appendix
(laparotomy) and systemic antibiotic therapy with amikacin for at
least one month. After this episode the family realized that, coin-
cidentally or not, he could not hear as well as before. In the
following years, there was a progressive worsening of the hearing
on both ears documented by audiometry (Fig. 2). At the age of 25,
after an episode of pneumonia treated with antibiotics, the
patient referred additional worsening in hearing loss and a new
symptom, tinnitus, on both ears. There were no complaints of
vestibular dysfunction or ear fullness. The EOG showed 1.8/
second spontaneous left beating nystagmus; normal gaze;
symmetrical gain and phase on the smooth pursuit; latency,
velocity and precision in normal range at the random horizontal
saccades; optokinetic with asymmetrical gain in 35/second
stimulation, with higher frequencies to the left, and normal range
gain in 20 and 50/second stimulations; and symmetric responses
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after caloric test stimulus on both ears. SHAT showed gain and
phase in normal range, and asymmetrical response in the
0.040 Hz frequency. OAE and BERA performed at the age of 27,
showed, on both ears, no response on distortion-product and no
response on click-evocated brainstem potential at 90dBHL,
respectively.
The father of the proband referred bilateral hearing loss that has
begun at the age of 13. He was seized with convulsions episodes
during his adolescence, with no apparent etiology and was treated
with trinuride. He denies additional symptoms such as vertigo,
tinnitus or ear fullness. OAE and BERA tests showed, at the age of
59, no response on distortion-product on both ears and no response
on click-evocated brainstem potential at 90dBHL, respectively. The
EOG showed a slight spontaneous left beating nystagmus (1.1/
second) with normal ocular motor tests (normal gaze; symmetrical
gain and phase on the smooth pursuit; latency, velocity and pre-
cision in normal range at the random horizontal saccades), except
for an asymmetric gain in 20, 35 and 50/seconds stimulations at
the optokinetic test (higher frequencies to the left); and symmetric
responses after caloric test stimulus on both ears. SHAT showed
gain, symmetry and phase in normal range at all tested frequencies.
CT scanning of the temporal bone excluded inner ear malfor-
mations; and MRI ruled out membranous labyrinth, eighth nerve
affection or other brain tumors, as source of symptoms in both
affected members.
2. Methods
After obtaining informed consent, peripheral blood was
collected and genomic DNA was isolated from family members.
Mutations often associated with hearing loss were discarded, spe-
ciﬁcally: c.35delG and c167delT GJB2 mutations, delGJB6
[D13S1830] and delGJB6 [D13S1854], mitochondrial A1555G mu-
tation and other mutations in the entire coding region of the GJB2
gene.
Array-CGH was performed by using genomic DNA from the
index patient and a platform from Oxford Gene Technology
(CytoSure ISCA v2 - 4x180k) containing 180,000 oligonucleotides
as described by the manufacturer. Data were processed with
Feature Extraction software (Agilent Technologies) and subse-
quently analyzed with the Genomic Workbench software (Agi-
lent Technologies). Gains and losses of genomic sequences were
called using an aberration detection statistical algorithm ADM-2,
with a sensitivity threshold of 6.7. Detected copy number varia-
tions (CNVs) were compared to data from oligoarray studies
documented in the Database of Genomic Variants [DGV; http://
projects.tcag.ca/variation/]. All variants present in at least four
different studies in DGV were considered as normal population
variants (common), and subsequently disregarded. Chromosome
regions not previously reported as CNVs were singled out for
further investigations, which included conﬁrmatory studies by
real-time quantitative PCR (qPCR) using the TaqMan Copy
Number Assays system (Applied Biosystems). A pre-designed
probe speciﬁc for the POU4F3 gene was used (assay ID
HS02668483_cn) along with a control probe (Rnase P gene).
Fig. 1. Family pedigree. The arrow indicates the proband.
Fig. 2. Pure-tone Audiometry Data Analysis Follow up of the proband. A. PTA at the age of 12 years old. B. PTA at the age of 14 years old. C. PTA at the age of 20 years old. D. PTA at
the age of 23 years old. E. PTA at the age of 25 years old. F. PTA at the age of 26 years old. SRT: Speech Reception Threshold; SDT: Speech Detection Threshold; WRS: Word
Recognition Score; RE: Right Ear; LE: Left Ear.
É.L. Freitas et al. / European Journal of Medical Genetics 57 (2014) 125e128126
3. Genomic rearrangement
Array-CGH analysis of the proband showed a deletion at 5q32
(145,682,536 bp to 145,738,485 bp region e NCBI Build 36, Feb
2007). The proximal breakpoint mapped between 145,658,445 bp
(A_16_P17337086 e last probe not deleted) and 145,682,536 bp
(A_16_P01358616 e ﬁrst deleted probe); while the distal break-
point was located between 145,738,485 bp (A_16_P17337308) and
145,796,051 bp (A_16_P17337434) (respectively, the last deleted
probe and the ﬁrst non-deleted probe) (Fig. 3A and B). The minimal
size of the deletion is 56 kb and the maximal size is 137 kb. Real-
time quantitative PCR analysis conﬁrmed the alteration and
revealed that the deletion is likely to be inherited from the affected
father (Fig. 3C).
4. Discussion
Here we report the ﬁrst ADNSHL familial case with a germline
deletion of the entire POU4F3 gene. The POU4F3 (POU class 4 ho-
meobox 3; OMIM 602460) gene is a member of the POU-domain
class IV transcription factor family, and it has 14 members in
humans. All these genes are characterized by the presence of two
DNA binding domains: a POU-speciﬁc domain and a POU homeo-
domain. The various POU proteins are involved in tissue-speciﬁc
gene regulation. The transcription factors POU4F1, POU4F2 and
POU4F3 are essential for the maturation and survival of motor and
sensory neural cells, retinal ganglion cells, and cochlear hair cell,
respectively [Vahava et al., 1998].
So far, fewmutations in the POU4F3 gene have been described in
patients with ADNSHL. The ﬁrst mutation, c.884del8, was found in
one Israeli pedigree [Vahava et al., 1998], two missense mutations
(p.L289F and p.L223P) were subsequently identiﬁed in Dutch
families [Collin et al., 2008] and one (c.662del14) in a Korean
patient [Lee et al., 2010]. Recently with the advances in new
technologies such as Next Generation Sequencing, two novel
mutations were described. A missense mutation, p.E232K, was
identiﬁed by Baek et al. [2012 Sep 3] and a novel c.603_604delGG
was predicted to lead to a truncated protein by Yang et al. [2013
Jun 14]. However, there are no reports of mutations in POU4F3 in
Brazilians, and no report of ADNSHL caused by germline large
Fig. 3. A. Ideogram of chromosome 5 showing the position of the deletion on the long arm (bar). In detail, the RefSeq gene located in the deleted area, the entire POU4F3 gene. B.
aCGH proﬁle of the chromosome 5 of the patient. The green bar points to the deleted probes site and represents the minimal deletion size. C. Real-time quantitative PCR data.
POU4F3 gene copy number (one) of the patient and his father were compared with that from control sample (two copies), conﬁrming the deletion in the patient and his father.
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deletions. All mutations described previously resulted in protein
with decreased binding to consensus DNA, reduced capability to
activate reporter gene expression, and partial mislocalization in
the cytoplasm. These functional studies indicate that both
missense as well as the frameshift mutations affects proper
functioning of the POU4F3 protein. Based on these results,
haploinsufﬁciency seems to be the most-likely mechanism under-
lying the hearing impairment in DFNA15-patients, and the deletion
of an entire copy of the POU4F3 gene in our patient is also in
agreement with this hypothesis. Apparently, even very low levels of
the protein are sufﬁcient to ensure proper vestibular function in
these individuals [Vahava et al., 1998].
According to the literature, DFNA15 patients have shown
varying rates of progression, as well as varying ages of onset for
hearing impairment and vestibular defects. In the Israeli family
[Vahava et al., 1998], hearing impairment appeared to be
moderate to severe, audiometric conﬁguration varied between
ﬂat and downsloping. The patients presented adult-onset pro-
gressive hearing loss, beginning between the ages of 18 and 30
years, without concomitant vestibular complains. Unlike the Is-
raeli family, some of the patients from the Dutch family [Collin
et al., 2008] presented vestibular symptoms, including
instability, vertigo, and a tendency to fall; and a mean subjective
onset of the hearing loss at the age of 35 years. The Korean
patient demonstrated a severe to profound sensorineural
hearing loss with no additional clinical symptoms [Lee et al.,
2010]. In the family described in this study, the phenotype onset
occurred between the ages 11e13 years for the two affected
members and progressed from moderate to severe deafness by
mid-age in the father, and from moderate to profound by adult-
hood in the proband. Even in the absence of vestibular complains,
we decided for a more accurate vestibular investigation, since the
previous clinical ﬁndings regarding POU4F3 gene mutations were
variable. The main ﬁndings at the vestibular tests points out to
some degree of visual-vestibular system asymmetry, but the
ﬁndings are so subtle that are in agreement with the absence of
vestibular complains described in other reports.
According to the clinical evaluation, the proband presented
profound sensorineural hearing loss and the father presented
moderate to severe sensorineural hearing loss. Although similar
molecular mechanisms underlie hearing loss in the patient and his
father, the clinical and audiometric phenotype were distinct in the
two affected members. A steeply downsloping audiogram was
noticed for the proband, with tinnitus, and a ﬂat to gently down-
sloping audiometric conﬁguration was observed for the father.
Despite the similar early onset of the bilateral sensorineural hear-
ing loss, the proband presented a signiﬁcant faster progression on
hearing loss along the years, unlike his father who showed slower
progression with advancing age. Amikacin is known to be ototoxic
and the exposure to this drug may somehow explain why the
proband hearing loss worsened so precociously. However, this
possible ototoxic effect alone does not explain the hearing loss
progression documented long after the treatment.
The differences in the clinical presentation in DFNA15 patients
reinforce the possibility that genetic proﬁle is under inﬂuence of
environmental factors, acting together to determine diversity of
clinical phenotypes.
Our results lend support to the relevance of CNVs in the etiology
of ADNSHL and they also support the importance of the array-CGH
technique. Sanger Sequencing is not suitable for quantiﬁcations
and, therefore, does not detect duplications and heterozygous de-
letions. MLPA, in contrast, allows detection of large deletions and
duplications. There are several commercial MLPA kits for ADNSHL,
but none of them include the POU4F3 gene. Next generation
sequencing technologies (NGS) provide an alternative method for
detecting copy number by the counting of sequence reads in non-
overlapping windows between patient and control samples. How-
ever, due to the relatively young age of the procedures, their per-
formance is not fully understood. As more mutations contributing
to hearing loss are identiﬁed, and thorough audiological analysis
are performed, comprehensive genotypeephenotype correlations
can be made for inherited non-syndromic hearing loss.
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